Antipsychotic medications: Metabolic and cardiovascular risk

被引:0
|
作者
Newcomer, John W. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Psychiat, Ctr Clin Studies, St Louis, MO 63110 USA
关键词
CORONARY-HEART-DISEASE; BODY-MASS INDEX; 2ND-GENERATION ATYPICAL ANTIPSYCHOTICS; VISCERAL ADIPOSE-TISSUE; INDUCED WEIGHT-GAIN; C-REACTIVE PROTEIN; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; EXCESS MORTALITY; SCHIZOPHRENIA;
D O I
暂无
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Individuals with serious mental illness experience excess morbidity and mortality, including an increased prevalence of diabetes mellitus and cardiovascular disease. Cardiovascular disease is the leading cause of death in persons with serious mental illness, and the elevated prevalence of obesity in this population is of particular concern. Obesity is an independent cardiometabolic risk factor that impacts morbidity and mortality and contributes to the development of other cardiometabolic risk factors, such as dyslipidemia and hypertension. In addition, obesity is a major risk factor for type 2 diabetes, with the relative risk of diabetes increasing with body mass index. Increased abdominal fat is strongly associated with insulin resistance, which can lead to impaired glucose regulation. Abdominal obesity, hyperglycemia, hypertension, and dyslipidemia are key components of the metabolic syndrome, a constellation of cardiometabolic risk factors linked by their common association with insulin resistance. Evidence from large clinical samples indicates a high prevalence of metabolic syndrome and all of its components in persons with serious mental illness, particularly in patients with schizophrenia. In addition, psychotropic agents, including some antipsychotic medications, are associated with substantial weight gain, as well as with adiposity-dependent and possibly adiposity-independent changes in insulin sensitivity and lipid metabolism, which increase the risk of diabetes and cardiovascular disease. Among the second-generation antipsychotics, clozapine and olanzapine are associated with the highest risk of substantial weight gain, similar to the weight gain potential associated with low-potency first-generation antipsychotics such as thioridazine or chlorpromazine, as well as with an increased risk of diabetes and dyslipidemia. Various strategies for monitoring cardiometabolic risk factors in patients with mental illness are discussed in this review.
引用
收藏
页码:8 / 13
页数:6
相关论文
共 50 条
  • [41] Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
    De Hert, Marc
    Detraux, Johan
    van Winkel, Ruud
    Yu, Weiping
    Correll, Christoph U.
    NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (02) : 114 - 126
  • [42] Fracture Risk in Nursing Home Residents Initiating Antipsychotic Medications
    Rigler, Sally K.
    Shireman, Theresa I.
    Cook-Wiens, Galen J.
    Ellerbeck, Edward F.
    Whittle, Jeffrey C.
    Mehr, David R.
    Mahnken, Jonathan D.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2013, 61 (05) : 715 - 722
  • [43] Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia?
    Palmer, DD
    Henter, ID
    Wyatt, RJ
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 100 - 103
  • [44] Second-Generation Antipsychotic Medications and Risk of Pneumonia in Schizophrenia
    Kuo, Chian-Jue
    Yang, Shu-Yu
    Liao, Ya-Tang
    Chen, Wei J.
    Lee, Wen-Chung
    Shau, Wen-Yi
    Chang, Yao-Tung
    Tsai, Shang-Ying
    Chen, Chiao-Chicy
    SCHIZOPHRENIA BULLETIN, 2013, 39 (03) : 648 - 657
  • [45] New Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects
    Pucci, Andrea
    Finer, Nicholas
    CANADIAN JOURNAL OF CARDIOLOGY, 2015, 31 (02) : 142 - 152
  • [46] Antipsychotic medications and fertility
    Currier, GW
    Simpson, GM
    PSYCHIATRIC SERVICES, 1998, 49 (02) : 175 - 176
  • [47] Switching antipsychotic medications
    Weiden, PJ
    Aquila, R
    Dalheim, L
    Standard, JM
    JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 : 63 - 72
  • [48] Adherence to antipsychotic medications
    Perkins, DO
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 25 - 30
  • [49] Antipsychotic Medications for Schizophrenia
    Fleischhacker, W. Wolfgang
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (14): : 1467 - 1468
  • [50] Arrhythmia and antipsychotic medications
    Chong, SA
    Mythily
    PSYCHIATRIC SERVICES, 2001, 52 (09) : 1257 - 1257